3/17
04:37 pm
nbix
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer [Yahoo! Finance]
3/17
04:05 pm
nbix
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
Neutral
Report
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
3/16
09:13 am
nbix
Neurocrine Biosciences: The Song Remains The Same [Seeking Alpha]
Low
Report
Neurocrine Biosciences: The Song Remains The Same [Seeking Alpha]
3/12
02:22 pm
nbix
Neurocrine Biosciences (NBIX) had its price target raised by JPMorgan Chase & Co. from $176.00 to $177.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NBIX) had its price target raised by JPMorgan Chase & Co. from $176.00 to $177.00. They now have an "overweight" rating on the stock.
3/10
04:01 pm
nbix
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
Low
Report
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
3/6
05:00 pm
nbix
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
Low
Report
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
3/3
02:06 pm
nbix
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Low
Report
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
2/25
06:24 am
nbix
Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".
Low
Report
Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".
2/24
04:29 pm
nbix
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
Low
Report
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
2/24
04:01 pm
nbix
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Low
Report
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
2/24
08:00 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.
2/19
07:26 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
2/18
09:49 pm
nbix
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza [Yahoo! Finance]
Low
Report
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza [Yahoo! Finance]
2/17
02:48 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $177.00 to $176.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $177.00 to $176.00. They now have an "overweight" rating on the stock.
2/17
11:53 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $169.00 to $140.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $169.00 to $140.00. They now have a "buy" rating on the stock.
2/16
01:08 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at
Wall
Medium
Report
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at
Wall
2/14
06:51 am
nbix
A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance [Yahoo! Finance]
Medium
Report
A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance [Yahoo! Finance]
2/13
09:47 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Wells Fargo & Company from $180.00 to $175.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Wells Fargo & Company from $180.00 to $175.00. They now have an "overweight" rating on the stock.
2/13
04:22 am
nbix
Neurocrine Biosciences: Growth Beyond Just Ingrezza [Seeking Alpha]
Low
Report
Neurocrine Biosciences: Growth Beyond Just Ingrezza [Seeking Alpha]
2/12
02:52 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $203.00 to $204.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $203.00 to $204.00. They now have a "buy" rating on the stock.
2/12
02:21 pm
nbix
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting [Seeking Alpha]
Low
Report
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting [Seeking Alpha]
2/12
12:52 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Royal Bank Of Canada from $180.00 to $177.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Royal Bank Of Canada from $180.00 to $177.00. They now have an "outperform" rating on the stock.
2/12
12:26 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at BMO Capital Markets from $147.00 to $140.00. They now have a "market perform" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at BMO Capital Markets from $147.00 to $140.00. They now have a "market perform" rating on the stock.
2/12
11:14 am
nbix
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says [Yahoo! Finance]
Low
Report
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says [Yahoo! Finance]
2/12
09:46 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Wedbush from $149.00 to $151.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Wedbush from $149.00 to $151.00. They now have an "outperform" rating on the stock.